Lantheus Holdings, Inc. (LNTH) said Thursday that the U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2026, for LNTH-2501.
LNTH-2501 is a diagnostic kit used to prepare Ga 68 edotreotide injection, indicated for use with positron positron emission tomography (PET) imaging to localize somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs) in adult and pediatric patients.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.